These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 9221990)

  • 1. Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome.
    Buyalos RP; Geffner ME; Azziz R; Judd HL
    Hum Reprod; 1997 Jun; 12(6):1138-41. PubMed ID: 9221990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion.
    Lanzone A; Fulghesu AM; Guido M; Fortini A; Caruso A; Mancuso S
    Fertil Steril; 1992 Aug; 58(2):296-301. PubMed ID: 1321739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women.
    Falcone T; Finegood DT; Fantus IG; Morris D
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1653-7. PubMed ID: 2146285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.
    Chen F; Chen M; Zhang W; Yin H; Chen G; Huang Q; Yang X; Chen L; Lin C; Yin G
    J Ovarian Res; 2021 Feb; 14(1):32. PubMed ID: 33583431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome.
    Farah-Eways L; Reyna R; Knochenhauer ES; Bartolucci AA; Azziz R
    Fertil Steril; 2004 Jan; 81(1):120-5. PubMed ID: 14711554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome.
    Tropeano G; Lucisano A; Liberale I; Barini A; Vuolo IP; Martino G; Menini E; Dell'Acqua S
    J Clin Endocrinol Metab; 1994 Feb; 78(2):305-9. PubMed ID: 8106616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
    Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
    Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Androgen response in women with polycystic ovary syndrome and hyperinsulinemia during stimulation with corticotrophin and inhibition with dexamethasone].
    Espinosa de los Monteros A; Guerra de la Garza A; Barrón J; Parra A
    Rev Invest Clin; 1996; 48(4):267-73. PubMed ID: 8966389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women.
    Azziz R; Bradley EL; Potter HD; Parker CR; Boots LR
    Am J Obstet Gynecol; 1995 Apr; 172(4 Pt 1):1251-6. PubMed ID: 7726265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.
    Sir-Petermann T; Maliqueo M; Angel B; Lara HE; Pérez-Bravo F; Recabarren SE
    Hum Reprod; 2002 Oct; 17(10):2573-9. PubMed ID: 12351531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of physiologic hyperinsulinemia during an oral glucose tolerance test on the levels of dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) in healthy young adults born with low and with normal birth weight.
    Vásárhelyi B; Bencsik P; Treszl A; Bardóczy Z; Tulassay T; Szathmari M
    Endocr J; 2003 Dec; 50(6):689-95. PubMed ID: 14709839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
    Sathyapalan T; Smith KA; Coady AM; Kilpatrick ES; Atkin SL
    Ann Clin Biochem; 2012 Jan; 49(Pt 1):80-5. PubMed ID: 21972424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression.
    Arlt W; Justl HG; Callies F; Reincke M; Hübler D; Oettel M; Ernst M; Schulte HM; Allolio B
    J Clin Endocrinol Metab; 1998 Jun; 83(6):1928-34. PubMed ID: 9626121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS).
    Kumar A; Woods KS; Bartolucci AA; Azziz R
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):644-9. PubMed ID: 15943823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome.
    Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.